Protalix BioTherapeutics (PLX) Cash & Equivalents (2010 - 2026)

Protalix BioTherapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $711000.0 for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 96.35% year-over-year to $711000.0; the TTM figure through Mar 2026 stood at $711000.0 (down 96.35% YoY), while the FY2025 annual figure was $702000.0, changed N/A from the prior year.
• Cash & Equivalents was $711000.0 for Q1 2026 at Protalix BioTherapeutics, up from $702000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $48.2 million in Q2 2023 to a low of $702000.0 in Q4 2025.
• Historically, Cash & Equivalents has averaged $19.6 million across 5 years, with a median of $18.7 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents soared 285.72% in 2023, then sank 96.35% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $17.1 million in 2022, then jumped by 38.12% to $23.6 million in 2023, then climbed by 15.97% to $27.4 million in 2024, then tumbled by 97.44% to $702000.0 in 2025, then gained by 1.28% to $711000.0 in 2026.
• The last three Cash & Equivalents figures came in at $711000.0 (Q1 2026), $702000.0 (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.